Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | CRHBP | P24387 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20129869 | 0.84 | MAPT (0.48) | HTR6MEN1KMT2AMAPTUSP2 | |
| SCHEMBL20129862 | 0.83 | HTR6 (0.56) | HTR6MEN1KMT2AMAPTUSP2 | |
| SCHEMBL20129863 | 0.82 | AURKA (0.46) | HTR6MEN1KMT2AMAPTNPC1 | |
| SCHEMBL29721814 | 0.82 | AURKA (0.46) | HTR6MEN1KMT2AMAPTNPC1 | |
| SCHEMBL17749119 | 0.82 | KCNQ3 (0.34) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL17749078 | 0.78 | KCNQ2 (0.47) | — | |
| SCHEMBL15348124 | 0.78 | KCNQ3 (0.51) | HTR6MEN1KMT2AMAPTUSP2 | |
| SCHEMBL17761665 | 0.78 | MAPT (0.46) | HTR6MEN1KMT2AMAPTCYP3A4 | |
| SCHEMBL20129873 | 0.76 | MAPT (0.57) | HTR6MEN1KMT2AMAPTHTT | |
| SCHEMBL15357266 | 0.76 | MAPT (0.46) | HTR6MEN1KMT2AMAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358930-B2 | Selective potassium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210238129-A1 | SELECTIVE POTASSIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-08-05 | — | — | US | disclosed |
| WO-2019203951-A1 | SELECTIVE POTASSIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20180127357-A1 | (2-AMINO-4-(ARYLAMINO)PHENYL) CARBAMATES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238129-A1 | SELECTIVE POTASSIUM CHANNEL AGONISTS | KCNH3, KCNH2, KCNJ11 | HTR6 712/4885MEN1 1257/4885KMT2A 905/4885 |
| US-20180127357-A1 | (2-AMINO-4-(ARYLAMINO)PHENYL) CARBAMATES | HRH4, H1-10, HDAC10 | HTR6 829/4885MEN1 1794/4885KMT2A 811/4885 |
| US-11358930-B2 | Selective potassium channel agonists | KCNH3, KCNH2, KCNJ11 | HTR6 712/4885MEN1 1257/4885KMT2A 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.